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Abstract
Background: Cachexia is a complex and multifactorial syndrome defined as severe weight loss and muscle wasting
which frequently goes unrecognised in clinical practice [1]. It is a debilitating syndrome, resulting in patients
experiencing decreased quality of life and an increased risk of premature death; with cancer cachexia alone
resulting in 2 million deaths per annum [2]. Most work in this field has focused on cancer cachexia, with cardiac
cachexia being relatively understudied – despite its potential prevalence and impact in patients who have
advanced heart failure. We report here the protocol for an exploratory study which will: 1. focus on determining the
prevalence and clinical implications of cardiac cachexia within advanced heart failure patients; and 2. explore the
experience of cachexia from patients’ and caregivers’ perspectives.
Methods: A mixed methods cross-sectional study. Phase 1: A purposive sample of 362 patients with moderate to
severe heart failure from two Trusts within the United Kingdom will be assessed for known characteristics of
cachexia (loss of weight, loss of muscle, muscle mass/strength, anorexia, fatigue and selected biomarkers), through
basic measurements (i.e. mid-upper arm circumference) and use of three validated questionnaires; focusing on
fatigue, quality of life and appetite. Phase 2: Qualitative semi-structured interviews with patients (n = 12) that meet
criteria for cachexia, and their caregivers (n = 12), will explore their experience of this syndrome and its impact on
daily life. Interviews will be digitally recorded and transcribed verbatim, prior to qualitative thematic and content
analysis. Phase 3: Workshops with key stakeholders (patients, caregivers, healthcare professionals and policy makers)
will be used to discuss study findings and identify practice implications to be tested in further research.
Discussion: Data collected as part of this study will allow the prevalence of cardiac cachexia in a group of patients
with moderate to severe heart failure to be determined. It will also provide a unique insight into the implications
and personal experience of cardiac cachexia for both patients and carers. It is hoped that robust quantitative data
and rich qualitative perspectives will promote crucial clinical discussions on implications for practice, including
targeted interventions to improve patients’ quality of life where appropriate.
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Background
Cachexia is a complex and multifactorial wasting syn-
drome, which frequently goes unrecognised in clinical
practice [3]. Cachexic patients experience significant loss
of muscle, as well as severe weight loss which cannot be
successfully treated with nutrition alone [1]. This causes
decreased quality of life for patients and an increased
risk of premature death [4], and is an issue of global
concern. For example, cachexia affects around 9 million
people worldwide (1% of the patient population) and is
also associated with a high mortality rate [5]. More spe-
cifically, 1.2 million individuals were estimated to be suf-
fering from cardiac cachexia in Europe during 2014,
with a 1-year estimated morality rate of 20–40% [3]. Ac-
cording to a consensus definition [1] published in 2008
(see Fig. 1 for representation), cachexia is present when
the patient has a weight loss of at least 5% in ≤12
months or BMI < 20 kg/m2, plus three of the following
five criteria: 1) Decreased muscle strength; 2) Fatigue; 3)
Anorexia; 4) Lean tissue depletion; 5) Abnormal bio-
chemistry: anaemia [haemoglobin < 120 g/L]; low serum
albumin [< 32 g/L]. Since its publication a number of
studies have challenged this definition [10, 11], and
whilst disease specific definitions have been discussed
[12] or developed [13] for other chronic illness, to date
none exists for cardiac cachexia. This highlights the de-
veloping nature of this field and the dearth of research
relating to fundamental aspects of this syndrome.
Cachexia is associated with a number of chronic con-
ditions, including cancer [13], renal disease [14, 15],
chronic obstructive pulmonary disease [16], stroke [17]
and heart failure (cardiac cachexia) [18], though the ma-
jority of research to date has focused on cancer cachexia
[13]. In terms of cardiac cachexia, most studies have de-
tailed its complex pathophysiology [19] and its detri-
mental impact on prognosis [20]. However, this work is
still in its infancy and many other basic aspects of this
syndrome remain poorly understood and understudied,
such as its prevalence and effect on the daily life of pa-
tients. This is particularly concerning, considering that
the number of individuals living with heart failure has
increased to epidemic proportions, due to an ageing
population [21] and advancements in heart failure treat-
ment [22]. Furthermore, this elderly population often
shows multiple co-morbidities (i.e. renal disease or can-
cer), making early identification of those with cachexia
even more vital. However, this task is challenging, con-
sidering the syndrome is poorly understood, there is no
disease specific definition for cachexia in heart failure,
and guidance on its key features have yet to be trans-
lated into everyday clinical practice in many countries.
Of the work completed to date in relation to cardiac
cachexia, prevalence rates are a good example of the
variability between studies; with some quoting approxi-
mately 10% of heart failure patients as cachexic [20, 23],
whilst others range more broadly from 16 to 42% [2].
Fig. 1 Diagnostic criteria for cachexia, adapted from [1]. * Lowest tertile [6]. ** Physical or mental weariness resulting from exertion; unable to
continue exercise at the same intensity without a decrease in performance [7]. *** Limited food intake (total intake of calories is less than 20 kcal/
kg body weight/d; < 70% usual food intake) [8]. **** Depletion of lean tissue (i.e. mid upper arm circumference < 10th percentile for age and
gender) [9]
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Within the UK, the prevalence of cardiac cachexia is
currently unknown; which is concerning as even conser-
vative prevalence estimates of 10% would mean a large
number of patients are managing this syndrome with
limited clinical recognition and support. Furthermore,
these numbers are only likely to increase, due to an age-
ing population and reports of increased annual incidence
of cachexia in New York Heart Association (NYHA)
class III and IV patients [24]. In addition to this lack of
prevalence data, there are limitations to the work that
has been published to date. For example, previous stud-
ies were quite variable in terms of the criteria used for
defining cardiac cachexia, with one requiring uninten-
tional weight loss of > 7.5% [25] and another > 6% [26].
Even more recent studies do not always adequately de-
fine cardiac cachexia, such as that by Rossignol et al.
[27]; which used a weight loss criterion of ≥5%, but in-
cluded none of the other variables from the consensus
definition [1]. Regardless of criteria used, many studies
also do not report a power calculation when describing
the sample sizes used, making it hard to determine if
they were sufficiently powered to support their conclu-
sions [23, 27, 28]. It is therefore crucial that the process
of diagnosing cardiac cachexia is improved and that
studies are conducted in a more standardised way. This
will allow better prevalence estimations and greater un-
derstanding of the biopsychosocial impact of the syn-
drome, paving the way for potential therapeutic
interventions [2, 29].
Another area which remains poorly studied is the psycho-
social effect of cachexia in those suffering from chronic ill-
nesses. For cancer cachexia, some research has been
undertaken to better understand the impact the syndrome
has on patient and caregiver quality of life [14, 15]. Such
work identified psychological, social and emotional issues
caused by cancer cachexia, which impact both patients and
their families; as well as a need for improved clinical inter-
ventions. However, in cardiac cachexia such data are lim-
ited, with only 1 study to date exploring the experience of
food and food intake among patients with heart failure [30].
This exploratory study found that loss of appetite also cre-
ated feelings of deprivation, with patients missing the social
aspects of eating. Qualitative research in other chronic ill-
nesses has displayed the multifaceted impact progressive
and involuntary weight loss has on both patients and their
caregivers. To date though, no studies including caregivers
have been conducted in relation to cardiac cachexia. These
qualitative studies are key to improving the understanding
of cardiac cachexia and its effect on daily life, and will hope-
fully lead to recommendations for the improvement of clin-
ical management.
The clinical management of patients with cardiac cach-
exia is challenging, in part due to the difficulty of discrimin-
ating cachexia from other symptoms which can occur with
advanced illness, and the lack of effective interventions.
Furthermore, there is a lack of both a disease specific defin-
ition for this syndrome and clinical guidelines for its man-
agement. Gaps in evidence have been identified and clinical
experts have asserted the need for quality studies on cardiac
cachexia and potential treatments [31, 32]. Of those gaps
discussed here, this study will focus on two main areas. The
first will be the prevalence and impact of cardiac cachexia,
focusing on outcomes such as fatigue and quality of life.
Secondly, a qualitative exploration, including patients with
cachexia and their caregivers, will uncover the impact this
syndrome has on daily life. It is hoped that presenting ro-
bust quantitative data and rich qualitative perspectives will
promote crucial discussions on implications for practice, in-
cluding targeted interventions to improve patients’ quality
of life.
Here we present a protocol for this exploratory study,
which will be approached through 3 phases of work:
1. Evaluate the prevalence and clinical implications of
cardiac cachexia in patients with NYHA Class III –
IV heart failure.
2. Explore the qualitative experience of cardiac
cachexia from patients’ and caregivers’ perspectives.
3. Consult with key stakeholders and define practice
implications of study findings.
Methods/design
Overall study design
This will be a mixed methods cross sectional study,
which is appropriate for addressing the study aim as
quantitative data will allow the current prevalence and
impact of the syndrome to be determined, whilst quali-
tative data will describe its effect on the daily lives of
patients and caregivers. In this study, participants will
be defined as having cardiac cachexia if they meet the
criteria of the 2008 consensus definition [1] (see Fig. 1
for representation). The study has three phases in total
(see Fig. 2).
Phase 1
Research design and setting
Phase 1, in line with the Evans et al. [1] definition, will
focus on gathering quantitative data by taking anthropo-
metric measurements and through the use of validated
questionnaires, on a purposive sample of 362 NYHA
class III and IV heart failure patients (see Table 1 for in-
clusion/exclusion criteria). NYHA class III and IV heart
failure patients are being targeted as cachexia tends to
impact patients at the end of the chronic natural course
of heart failure, and therefore these individuals are more
likely to be suffering from the syndrome [31]. The set-
ting for this work will be heart failure wards, outpatient
departments and ambulatory clinics in hospitals at two
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healthcare Trusts within the UK. Participants will be re-
cruited over an 18-month period, ending in November
2020. A private space will be used for data collection,
such as an empty private room at the clinic/ward, or a
quiet area with a privacy screen. If willing and eligible to
participate, heart failure patients will have a number of
simple measures taken by the researcher, including: 1.
Muscle mass (by measuring mid-upper arm circumfer-
ence); 2. Muscle strength (using a handheld dynamom-
eter), and; 3. Skinfold thickness (using skin callipers).
Each of these are common measures which are routinely
used to determine if a patient is suffering from cachexia
and to what degree. Each measure is non-invasive and
will take 1–2 min to complete.
Subsequently, participants will complete three short, vali-
dated questionnaires: 1. FACIT (Functional Assessment of
Chronic Illness Therapy) Fatigue Scale; 2. FAACT (Func-
tional Assessment Anorexia/Cachexia Therapy scale), and;
3. EuroQOL (EQ-5D-5 L) questionnaire (quality of life).
The FACIT-fatigue scale is used to measure fatigue and a
conditions impact on daily life within the general popula-
tion [33]; making it a useful tool to address the aims and
objectives of this study. Furthermore, it has been effective
in identifying fatigue in people suffering from chronic
Fig. 2 Flow diagram, showing basic detail of the three phases of the study
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illnesses [34, 35], including cardiac disease [36, 37].
Similarly, the FAACT questionnaire is widely used in the
literature, focusing on assessing appetite and related
symptoms - particularly in cancer focused studies. For ex-
ample, the questionnaire has been shown to aid clinicians
when testing the efficacy of anti-anorexia/cachexia therap-
ies [38, 39], whilst also correlating well with other self-
report scales and questionnaires [40]. Finally, the EQ-5D-5
L is widely used to determine quality of life, particularly
with chronic conditions such as heart failure [41–43]. The
use of these validated, common and robust questionnaires/
scales will improve the rigour of this study, whilst each is
also short and easy to complete – reducing participant
burden.
Participants will also be invited to complete a short
demographic questionnaire comprised of questions con-
cerning their weight, gender, marital status, postcode and
any co-morbidities. This information will be used to select
a representative sample for phase 2. The participant will
be invited to complete anthropometric measurements/val-
idated questionnaires directly after a scheduled appoint-
ment with their clinical team. Data collection should take
20min or less. Willing participants will also consent to
their medical records being accessed for information rele-
vant to the study, such as blood marker levels and weight.
Sample size calculation
With a total sampling frame of 6062 patients, a 5% margin
of error, 95% confidence level and a response distribution
of 50%, the recommended sample size for phase 1 of this
study is 362 participants. This was calculated using Raosoft
software [44].
Recruitment procedure
Two weeks prior to the start of patient recruitment, posters
referring to the study will be placed in reception and wait-
ing areas that are frequented by patients. Subsequently,
clinical gatekeepers (Cardiac/Specialist Nurses and/or Con-
sultant Cardiologists) will review the records of patients
that may fit the study criteria. If a patient is eligible the
gatekeeper will inform the patient of the study at their next
scheduled appointment and provide an information pack,
including an invitation to participate and study information
sheet. If the patient is interested in participating they will
be directed to the researcher after their appointment, who
will give more detail on the study and obtain informed
consent, before the completion of anthropometric measure-
ments and validated questionnaires.
Variables, data sources and measurement
For patients to be classed as suffering from cardiac cach-
exia they must have experienced weight loss and 3 out of
5 other criteria (see Fig. 1 for detail). Relating to this, there
will be a total of 8 outcomes in phase 1 of the study:
1. Mid-upper arm circumference (continuous data)
2. Skinfold thickness (continuous data)
3. Muscle strength (continuous data)
4. Weight and BMI (continuous data)
5. Blood measures (continuous data)
6. FACIT (Functional Assessment of Chronic Illness
Therapy) Fatigue Scale (ordinal data)
7. FAACT (Functional Assessment Anorexia/Cachexia
Therapy scale) (ordinal data)
8. EuroQOL five dimensions (EQ-5D) questionnaire
(quality of life) (ordinal data)
Mid-upper arm circumference, skinfold thickness and
muscle strength are all measurements that will be coor-
dinated by the researcher. Measurement error will be re-
duced as much as possible by following a standard
protocol for each measurement. Muscle strength meas-
urement will be completed by the patient under the dir-
ection of the researcher, with the same clear instruction
given to each participant. Weight will be obtained from
patient records, as well as being self-reported on the
cover information sheet, and therefore cannot be further
controlled. BMI will be calculated using weight and
height data. The two scales and questionnaire will be
completed by the patient and therefore measurement
error also cannot be controlled. However, each tool is
validated and commonly used within the literature,
whilst the researcher will also be on hand to offer extra
explanation if necessary.
Confounding variables
As heart failure is associated with an increasing elderly
population it often presents with other co-morbidities, such
as renal disease or cancer. As such, the presence of these
conditions may influence patient weight loss and therefore
the determination of cardiac cachexia in this study. Further-
more, any treatments/medications prescribed for co-
morbidities may influence the study outcomes. However, in
the present study there is minimal scope to control for con-
founding variables for two main reasons: 1. Controlling for
every variable is not feasible; and, 2. Co-morbidities are
Table 1 Inclusion and exclusion criteria for patients
participating in phase 1
Inclusion criteria Exclusion criteria
Are aged 18 and over Lacking capacity to give consent
Able to read, write and speak English Under the age of 18
Confirmed diagnosis of advanced heart
failure (NYHA class III-IV)
Physically and mentally capable of
participation (judged by cardiologist)
Willing to be involved
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characteristic of the general heart failure population, and
therefore by excluding these patients a representative sample
would not be achieved. However, information will be col-
lected concerning co-morbidities and medication use for
each participant, which will be referred to when making
conclusions from study data.
Data analysis
Quantitative data will be entered into SPSS version 25 or
above and analysed. Firstly, those individuals meeting the
agreed criteria for cardiac cachexia will be identified,
based on their weight loss and the meeting of other cri-
teria (e.g. fatigue and blood markers). Subsequently, the
prevalence of cardiac cachexia in the sample of advanced
heart failure patients will be determined, using a basic
proportion calculation. Univariate and multivariate regres-
sion analysis will be used to determine the relationship of
weight loss to the other criteria measured in phase 1, like
participants’ scores on various questionnaires and mid-
upper arm circumference – similar to previous work [20].
Before carrying out this analysis the dataset will be tested
to ensure it meets the assumptions of regression, such as
normality and homoscedasticity [45]. Data will also be
split into groups based on the degree of cachexia partici-
pants are suffering from (i.e. no cachexia, mild and severe
cachexia). Subsequently, differences between groups for
measures (such as score on questionnaires) will be deter-
mined using MANOVA (multivariate analysis of variance),
as in related work [46]. As with regression analysis, before
conducting MANOVA the data will be tested to check it
meets the assumptions of the test – such as normality and
equality of variance. If data is not normally distributed an
appropriate transformation will be applied, before using
an alternative non-parametric test. For missing data, the
mean of completed items will be substituted in place of
the missing value, where less than 50% of items are miss-
ing [47]. If more than 50% of items are missing the partici-
pant will be excluded from analysis. For all analysis, a p
value of 0.05 or less will be deemed statistically significant.
All data analysis will be reviewed by one statistician on the
research team and one independent statistician.
Phase 2
Research design and setting
From our phase 1 analysis, a purposive sample of 12 patients
who have cardiac cachexia [1] will be asked to take part in a
semi-structured interview, which is expected to last approxi-
mately 45min. These individuals will have agreed to be con-
tacted regarding an interview as part of phase 1. Additional
characteristics including gender, age, postcode and any co-
morbidities will also be taken into account when selecting
potential participants; to ensure a representative sample of
the total moderate to severe heart failure population is
achieved. Information collected during phase 1 will be used
to inform this selection process. Each patient will be asked
to nominate a caregiver (n = 12) who will be invited to
complete an interview (see Table 2 for inclusion and exclu-
sion criteria). Interviews will be conducted in a location of
the participant’s choice, such as their own home or a private
room on University premises. A core set of open-ended
questions in a “laddered style approach” [48] will be used,
focusing on the holistic impact and experience of cachexia
(see Fig. 3 for topic guide).
Sample size
The exact sample size will be determined by data satur-
ation [49]; however, drawing on previous work [50], 12
patients and 12 caregivers for this exploratory phase is
an indicative estimate.
Recruitment procedure
As part of the original consent process, phase 1 partici-
pants will have already agreed to be potentially con-
tacted about phase 2. Each selected patient participant
for phase 2 will receive a telephone call and asked if they
would like to receive postal information about this phase
of the study. Phone calls with patients will take place a
week or less after their participation in phase 1, to re-
duce the likelihood of their health deteriorating between
phase 1 and 2 of the study. The patient will then be
given a 1 week cool-off period, before a second phone
call will be placed to see if they would like to arrange an
interview. Upon interviewing the patient, an invitation to
participate and study information sheet will also be left
Table 2 Inclusion and exclusion criteria for patients and
caregivers participating in phase 2
Inclusion criteria Exclusion criteria
Patients
Same as phase 1 Not identified as suffering
from cardiac cachexia
(based on the results
of phase 1)
Caregivers
Are aged
18 and over
Lacking the capacity
to give consent
Able to read, write
and speak English
Under the age of 18
Have face-to-face
contact with the
patient more than
5 times per week
Be nominated
by the patient
Be physically and
mentally capable
of participation
(self-assessment)
Willing to be involved
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for the caregiver, with instructions to call the researcher
should they wish to participate in an interview. As
patients and caregivers have regular face-to-face contact
this will allow the study information to be passed on to
the caregiver. Written informed consent will be obtained
prior to interview. All interviews will be digitally
recorded.
Data analysis
Following verbatim transcription of the interviews, the
qualitative data will be subjected to a rigorous process of
thematic analysis by the research team, who are experi-
enced in this area. Transcripts will be analysed using a
6-step process [51], with data first being coded before
collating related codes and identifying potential themes.
One researcher will complete this initial analysis and
subsequently the research team will meet to review the
data; ensuring that themes identified are consistent with
the data and accurately represent the views of partici-
pants. Content analysis, using an inductive approach,
will also be used [52], to help code data and identify the
main themes within patient and caregiver experiences.
Both thematic and inductive content analysis are appro-
priate methods to use; as the systematic and categorizing
approach allows large amounts of text to be analysed in
terms of word frequency, their relationships and struc-
tures [51–53]. Furthermore, both are suitable given the
exploratory nature of this work, as neither relies upon
existing hypotheses or knowledge relating to the re-
search area.
Phase 3
Research design and setting
Results from phases 1 and 2 will be used to inform work-
shops, including 24 patients and caregivers from phase 2
(workshop 1) and key stakeholders such as cardiac multi-
disciplinary health care professionals and policy makers
(workshop 2). Attendance will be voluntary and it is ex-
pected that each workshop will last approximately 2 h.
These workshops have been separated so that we can en-
sure results are discussed in a sensitive fashion around pa-
tients and caregivers, and to minimise the potential for any
distress occurring. The format for the workshops will be
based on ‘co-design working groups’ approach [54], where
participants are mixed together; ensuring a diverse range of
perspectives and opinions in each group. After a short pres-
entation of the study’s findings, each group will be given a
set of findings and questions to discuss and make conclu-
sions about. Subsequently, the research team will review
each team’s findings and lead a discussion with all partici-
pants, focusing on areas of disagreement or confusion and
any recommendations for future clinical practice. This data
will be used to determine the importance of study findings
to different stakeholders and, hopefully, to generate ideas
Fig. 3 Topic guide, for use in the semi-structured interviews of phase 2 with patients and caregivers
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for further research that will lead to improvements in
practice.
Ethical considerations
This study will be conducted in compliance with Good
Clinical Practice Guidelines [55]. Ethical approval was
sought from the North East – Tyne & Wear South
Research Ethics Committee (19/NE/0121) and from the
Belfast and South Eastern Health and Social Care Trusts.
Fundamental aspects of good practice, including user
friendly information sheets, informed consent, voluntary
participation, confidentiality and data protection proce-
dures will be applied as a minimum standard. As this study
discusses a sensitive topic in a vulnerable population, it is
accepted that distress may occur - particularly during the
interviews of phase 2. As such, a distress protocol has been
developed for use with both patients and caregivers. Simi-
larly, the laddered style approach of questioning during
interviews will also reduce distress, allowing the mood of
participants to be gauged and future questioning to be
adapted appropriately. Furthermore, the study has been de-
signed to minimise the burden on participants as much as
possible. For example, only validated questionnaires are be-
ing used, whilst each of the three measurements that will
be taken are fairly quick to complete and non-invasive.
Study withdrawal
Participants will be advised of the voluntary nature of
their inclusion in this research and can withdraw at any
point, without compromising their current clinical care.
As stated in the information sheet, we will use collected
data up to the withdrawal point (with the participant’s
consent). The reason for withdrawal will be noted for fu-
ture review.
Discussion
This study will explore the prevalence, clinical implications
and experience of cardiac cachexia within a population of
NYHA class III and IV heart failure patients; whilst the
experience of caregivers will also be investigated. This
research has been designed to address many of the gaps in
the knowledge base within this field, which has typically
focused on cancer cachexia [13]. As such, prevalence rate
estimations for cardiac cachexia vary globally [2, 20, 23]
and are poorly understood within the UK; meaning even
the basic prevalence data from this study has the potential
for significant clinical impact. For example, given the poor
clinical recognition of cachexia, determining its prevalence
may help to highlight the importance of the syndrome to
healthcare providers. Obtaining data on how it impacts fac-
tors such as fatigue, quality of life and measurements like
mid-upper arm circumference may develop this further;
highlighting the fact that management of cachexia should
be prioritised whilst treating those with chronic illnesses.
Data from this study is therefore expected to help with the
future treatment of patients, as well as planning and the al-
location of resources. In addition to this, phase 1 data col-
lection is novel in terms of the range of data that will be
collected, as similar studies either focus on biochemical
characteristics [20, 56], anthropometric measurements [57,
58] or some combination of the two [11, 43]; whereas this
study will include both, as well as data from self-report
tools investigating fatigue, quality of life and appetite.
Another novel aspect of this study is its inclusion of
qualitative data, as only one study to date has explored the
perspectives of patients diagnosed with cardiac cachexia
[30]. Furthermore, unlike previous work [30], the present
study will include the views of caregivers; as these individ-
uals have a significant impact on the patients day to day
life, as well as being impacted themselves [15]. For ex-
ample, one review highlighted the profound psychosocial
impact that cancer cachexia has on both patients and
caregivers [29], suggesting that similar issues may be
present in those suffering from cardiac cachexia.
Overall, it is hoped that discussion of study findings will
lead to recommendations for further research and improve-
ments to clinical practice (such as care guidelines and
patient care pathways). A better understanding of the
syndrome and its effect on the daily life of patients and care-
givers will enable proposed interventions to be holistic and
patient centred, recognising and responding to the needs of
this client group. Any potential interventions should also
have international applicability, as this study will use the
consensus definition of cachexia [1] to define its population
and builds upon similar work in terms of study design [15,
20, 30, 43, 58]; though understandably more work will be
required to determine the applicability of any recommenda-
tions to different countries. Unfortunately, to date there is
no agreed ‘gold standard’ effective treatment for cachexia in
any chronic illness. Similarly, clinical management of cach-
exia in persons with advanced heart failure is undoubtedly
challenging, due to the polysymptomatic nature of cachexia,
the numerous co-morbidities that affect this patient popula-
tion and the lack of a disease specific definition. As such, it
is crucial that this study and those similar to it are
conducted, so that clinical recognition and management im-
prove – along with the quality of life and survival of individ-
uals with this syndrome.
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